ASLAN Pharmaceuticals Entered into a License Agreement with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
- ASLAN to receive $12M up front & an additional $3M upon achievement of pre-agreed conditions for the P-IIb trial (TREK-AD) data, ~$29.5M in development milestones, ~$94M in commercial milestones along with royalty on net sales of eblasakimab
- Zenyaku to get an exclusive right to develop & commercialize eblasakimab in AD & all other indications in Japan & will lead all development & commercialization activities for eblasakimab in Japan
- ASLAN holds an option that can be exercised at any time to reacquire the rights to eblasakimab in Japan in the future while the P-I study of eblasakimab is expected to be initiated in Japan in H1'24. Eblasakimab is being studied in the P-II trial (TREK-DX) for AD with expected results in Q1’24
Ref: Globe Newswire | Image: ASLAN
Related News:- ASLAN Reports First Patient Enrollment in P-IIb (TREK-AD) Study of ASLAN004 (eblasakimab) for the Treatment of Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.